Advertisement
Screener

CERO THERAPEUTICS HOLDINGS, INC. (CERO) Other General and Administrative Expense

2.8 / 5 stars · 68/120 Roast Me

CERO THERAPEUTICS HOLDINGS, INC. Other General and Administrative Expense

CERO THERAPEUTICS HOLDINGS, INC. (CERO) reported Other General and Administrative Expense of $843.62 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:OtherGeneralAndAdministrativeExpense · last filed 2026-08-14

  • CERO THERAPEUTICS HOLDINGS, INC. other general and administrative expense for the quarter ending 2026-06-30 was $843.62K, a 551.41% increase year-over-year.
  • CERO THERAPEUTICS HOLDINGS, INC. other general and administrative expense for the quarter ending 2026-03-31 was $1.11M, a 379.86% increase year-over-year.
  • CERO THERAPEUTICS HOLDINGS, INC. other general and administrative expense for the quarter ending 2025-12-31 was $197.66K.
  • CERO THERAPEUTICS HOLDINGS, INC. other general and administrative expense for the quarter ending 2025-09-30 was $82.22K, a 72.59% decline year-over-year.
  • CERO THERAPEUTICS HOLDINGS, INC. other general and administrative expense for fiscal 2025 was $824.71K.
  • CERO THERAPEUTICS HOLDINGS, INC. other general and administrative expense for fiscal 2023 was $5.23K.
Period endOther General and Administrative Expense 2 monthOther General and Administrative Expense 3 monthOther General and Administrative Expense 5 monthOther General and Administrative Expense 6 monthOther General and Administrative Expense 8 monthOther General and Administrative Expense 9 monthOther General and Administrative Expense 11 monthOther General and Administrative Expense 12 month
2026-06-30$843.62K
10-Q · filed 2026-08-14
$1.96M
10-Q · filed 2026-08-14
$2.15M
derived: sum of 3 quarters · filed 2026-08-14
$2.24M
derived: sum of 4 quarters · filed 2026-08-14
2026-03-31$1.11M
10-Q · filed 2026-05-15
$1.31M
derived: sum of 2 quarters · filed 2026-05-15
$1.39M
derived: sum of 3 quarters · filed 2026-05-15
$1.52M
derived: sum of 4 quarters · filed 2026-08-14
2025-12-31$197.66K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15
$279.89K
derived: sum of 2 quarters · filed 2026-04-15
$409.40K
derived: sum of 3 quarters · filed 2026-08-14
$824.71K
10-K · filed 2026-04-15
2025-09-30$82.22K
10-Q · filed 2025-11-19
$211.73K
derived: sum of 2 quarters · filed 2026-08-14
$627.04K
10-Q · filed 2025-11-19
2025-06-30$129.51K
10-Q · filed 2026-08-14
$361.15K
10-Q · filed 2026-08-14
2025-03-31$231.64K
10-Q · filed 2026-05-15
2024-12-31$376.76K
10-K · filed 2026-04-15
2024-09-30$300.00K
10-Q/A · filed 2024-11-20
$984.37K
10-Q · filed 2025-11-19
2024-06-30$849.95K
10-Q · filed 2025-08-22
2024-03-31$0.06
10-Q · filed 2024-05-17
2023-12-31$5.23K
10-K · filed 2025-04-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)United States$0.006B
AIM ImmunoTech Inc. (AIM)United States$0.006B
TScan Therapeutics, Inc. (TCRX)United States$0.008B-1.23
PharmaCyte Biotech, Inc. (PMCB)United States$0.005B
WINDTREE THERAPEUTICS INC /DE/ (WINT)United States$0.003B-0.32
VivoSim Labs, INC. (VIVS)United States$0.003B
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70
Calidi Biotherapeutics, Inc. (CLDI)United States$0.003B
IN8BIO, INC. (INAB)United States$0.012B-0.76
CURIS INC (CRIS)United States$0.002B-0.05